<SEC-DOCUMENT>0001178913-21-002877.txt : 20210901
<SEC-HEADER>0001178913-21-002877.hdr.sgml : 20210901
<ACCEPTANCE-DATETIME>20210901083014
ACCESSION NUMBER:		0001178913-21-002877
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210901
FILED AS OF DATE:		20210901
DATE AS OF CHANGE:		20210901

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Entera Bio Ltd.
		CENTRAL INDEX KEY:			0001638097
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38556
		FILM NUMBER:		211228864

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
		BUSINESS PHONE:		972-2-532-7151

	MAIL ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2126524.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 7.5.1.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div id="DSPFPageHeader">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">UNITED STATES</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM 6-K</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">For the month of September 2021</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Commission file number: 001-38556</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">ENTERA BIO LTD.</div>
      <div style="text-align: center; line-height: 1.25;">(Exact Name of Registrant as Specified in Its Charter)</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Kiryat Hadassah<br>
        Minrav Building &#8211; Fifth Floor</div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">Jerusalem, Israel</font><br>
        (Address of principal executive office)</div>
      <div style="text-align: center; line-height: 1.25;">_____________________</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Form 20-F &#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F &#9744;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;"><u>CONTENTS</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">This report on Form 6-K of the registrant consists of a press release issued by the registrant on September 1, 2021, attached hereto
          as an exhibit and incorporated by reference herein.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25;">This report on Form 6-K and Exhibit 99.1 hereto shall be deemed to be incorporated by reference into the registration statements on
          Form F-3 (Registration Number: 333-238988) and Form F-3 (Registration Number: 333-239843) of Entera Bio Ltd. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently
          filed or furnished.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;"><u>Exhibit</u></div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zf52e816d17904b4e8f986c0ab0851f52" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_99-1.htm">Exhibit
                  99.1:</a></div>
            </td>
            <td style="width: 92%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_99-1.htm">Press
                  release dated September 1, 2021.</a></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>SIGNATURES</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
        behalf by the undersigned, thereunto duly authorized.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zf974d762bd5b40a28f427f8d0273764d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.99%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">
              <div style="line-height: 1.25; font-weight: bold;">ENTERA BIO LTD.</div>
              <div style="line-height: 1.25;">(Registrant)</div>
            </td>
            <td style="width: 20%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.99%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 27%; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.99%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="line-height: 1.25;">By:</div>
            </td>
            <td nowrap="nowrap" style="width: 27%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">/s/ Spiros Jamas, Sc.D</div>
            </td>
            <td style="width: 20%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.99%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td nowrap="nowrap" style="width: 27%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Name: Spiros Jamas, Sc.D</div>
            </td>
            <td style="width: 20%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.99%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 27%; vertical-align: top;">
              <div style="line-height: 1.25;">Title: Chief Executive Officer and Director</div>
            </td>
            <td style="width: 20%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.99%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 27%; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;">Date: September 1, 2021</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 7.5.1.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div id="DSPFPageHeader">
        <div style="line-height: 1.25;"><img width="101" height="57" src="image0.jpg"></div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">&#8210; Second of Two Presentations to be Delivered by Entera &#8210;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">&#8210; Final 6-Month Bone Mineral Density (BMD) Results Show Dose-Related Efficacy &#8210; &#160; </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25;"><font style="font-weight: bold;">BOSTON, Massachusetts &amp; JERUSALEM, Israel &#8211; September 1, 2021 </font>&#8211; Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule
            therapeutics, today announced it has been selected by the 2021 Program Committee of the American Society for Bone and Mineral Research (ASBMR) Annual Meeting for a late breaking oral presentation titled &#8220;A Six-month Phase 2 Study of Oral PTH in
            Postmenopausal Women with Low Bone Mass &#8211; 6 Month Bone Mineral Density (BMD) results&#8221;.&#160; The ASBMR Annual Meeting is scheduled to take place on October 1-4, 2021, in San Diego, California. Entera was previously selected for a poster presentation
            of the same Phase 2 study&#8217;s 3-month results.</div>
          <div style="line-height: 1.25">&#160;</div>
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Details for both presentations are as follows:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><u>3-Month Results</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="za5a0efea8c124e9f9b3828d9b60ff1d6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Abstract Title:</font> A Six-month Phase 2 Study of Oral PTH in Postmenopausal Women with Low Bone Mass - An Interim Three-Month Analysis</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zf9e8ab4fa4d948d8b31853fb9a5883e7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Presentation Type:</font> Poster Presentation</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zec73c05cd6c04ffb8e22293786d71f34" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Dates/Times:</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z059cacad06b24b36a62f13df5cb5e742" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">o</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Biotechnology of Aging Skeleton Symposium &#8211; Thursday, September 30, 2021</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z1572f96f6ed04a978d866ec46c94c38d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">o</td>
            <td style="width: auto; vertical-align: top;">
              <div>Plenary Session &#8211; 5:00 pm PT Friday, October 1, 2021 </div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="ze7999e9ded6f49b585726bfc2159ba26" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">o</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>General Session &#8211; 1:00 pm PT Saturday, October 2, 2021</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zb4bf94bb352841b08c60ad176da4dff7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Presenter:</font> Dr. Arthur Santora, Entera&#8217;s Chief Medical Officer</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><u>6-Month Results</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="za3a49895a0d6425192d94b2d2f8eca40" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Abstract Title:</font> A Six-month Phase 2 Study of Oral PTH in Postmenopausal Women with Low Bone Mass &#8211; 6 Month Bone Mineral Density (BMD) results</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zf88558243b2b4344b45e7c1b915448e6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Presentation Type:</font> Oral Presentation</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z077b64d025564ac1b2b961e5560dc11a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Date/Time:</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z03617d3bd9cd46aebe642b65b682fd62" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">o</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Late Breaking: Clinical Treatment &#8211; 12:15 pm PT Monday, October 4, 2021</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z5843bebb3c874e2ca540bfb5bf88faf8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Presenter:</font> Dr. Arthur Santora, Entera&#8217;s Chief Medical Officer</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25">
          <div style="line-height: 1.25;">&#8220;As we prepare for our pivotal Phase 3 study we expect it will be very productive to present EB613 as a promising oral alternative
            for the treatment of osteoporosis to physicians and clinical investigators potentially looking to participate in the study or consider prescribing EB613 upon regulatory approval. As further validation of the significance of our results, the feedback following the stringent peer review process has been very positive and according to the ASBMR, the presentation is expected to receive a lot of attention at
              the upcoming scientific meeting,&#8221; stated Entera CEO Spiros Jamas</div>
          <div style="line-height: 1.25">&#160;</div>
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Entera Bio</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to
        cost, convenience and compliance challenges for patients. The Company&#8217;s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to
        the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company&#8217;s
        most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in clinical development. The Company recently completed the Phase 2 study for EB613. Entera also licenses its technology
        to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit <u>www.enterabio.com</u>.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Forward Looking Statements</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Various statements in this release are &#8220;forward-looking statements&#8221; under the securities laws. Words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221;
        &#8220;design,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; and &#8220;would,&#8221; or the negative of these terms and similar expressions or words, identify forward-looking statements.
        Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be
        accurate indications of when such performance or results will be achieved.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Important factors that could cause actual results to differ materially from those reflected in Entera&#8217;s forward-looking statements include, among others: changes in our interpretation of the
        complete 3-month biomarker data from the recently completed Phase 2 clinical trial of EB613, the timing of data readouts from the recently completed Phase 2 clinical trial of EB613, the full results of the Phase 2 clinical trial of EB613, and our
        analysis of those full results, the FDA&#8217;s interpretation and review of our results from and analysis of our Phase 2 trial of&#160; EB613, unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our
        ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the impact of COVID-19 on Entera&#8217;s business operations; the potential disruption and delay of manufacturing supply chains, loss of available
        workforce resources, either by Entera or its collaboration and laboratory partners, due to travel restrictions, lay-offs or forced closures or repurposing of hospital facilities; impacts to research and development or clinical activities that
        Entera is contractually obligated to provide, such as those pursuant to Entera&#8217;s agreement with Amgen; overall regulatory timelines, if the FDA or other authorities are closed for prolonged periods, choose to allocate resources to review of
        COVID-19 related drugs or believe that the amount of Phase 2 clinical data collected are insufficient to initiate a Phase 3 trial, or a meaningful deterioration of the current political, legal and regulatory situation in Israel or the United
        States; the availability, quality and timing of the data from the Phase 2 clinical trial of EB613 in osteoporosis patients; the ability to find a dose that demonstrates the comparability of EB613 to FORTEO in the recently completed&#160; Phase 2
        clinical trial of EB613; the size and growth of the potential market for EB613 and Entera&#8217;s other product candidates including any possible expansion of the market if an orally delivered option is available in addition to an injectable formulation;
        the scope, progress and costs of developing Entera&#8217;s product candidates including EB612 and GLP-2; Entera&#8217;s reliance on third parties to conduct its clinical trials; Entera&#8217;s expectations regarding licensing, business transactions and strategic
        collaborations; Entera&#8217;s operation as a development stage company with limited operating history; Entera&#8217;s ability to continue as a going concern absent access to sources of liquidity; Entera&#8217;s expectations regarding its expenses, revenue, cash
        resources, liquidity and financial condition; Entera&#8217;s ability to raise additional capital; Entera&#8217;s interpretation of FDA feedback and guidance and how such guidance may impact its clinical development plans; Entera&#8217;s ability to obtain and
        maintain regulatory approval for any of its product candidates; Entera&#8217;s ability to comply with Nasdaq&#8217;s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States;
        Entera&#8217;s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the &#8220;Special Note Regarding Forward-Looking Statements,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis
        of Financial Condition and Results of Operations&#8221; sections of Entera&#8217;s annual and current filings which are on file with the SEC and available free of charge on the SEC&#8217;s website at http://www.sec.gov. Additional factors may be set forth in those
        sections of Entera&#8217;s Annual Report on Form 20-F for the year ended December 31, 2020, filed with the SEC in the first quarter of 2021. In addition to the risks described above and in Entera&#8217;s annual report on Form 20-F and current reports on Form
        6-K and other filings with the SEC, other unknown or unpredictable factors also could affect Entera&#8217;s results. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially
        realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">All written and verbal forward-looking statements attributable to Entera or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or
        referred to herein. Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Entera
        undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Contact:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Spiros Jamas, CEO</div>
      <div style="line-height: 1.25;">Tel: +001 617-362-3579</div>
      <div style="line-height: 1.25;"><u>spiros@enterabio.com</u></div>
    </div>
    <div> <br>
    </div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- (@# 2(  A$! Q$!_\0
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D'Z9+:V\U[<*5DN,;5(Y"^OXFBNFHKKHTE2@H+H:PBHQLC__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
